Vanguard Capital Management
TLSI icon

Vanguard Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Vanguard Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.87M Buy
1,729,385
+382,349
+28% +$1.52M ﹤0.01% 2949
2026
Q1 		$5.39M Buy
+1,347,036
New +$6.6M ﹤0.01% 3033

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Vanguard Capital Management's TLSI Position: Q2 2026 in Review

Vanguard Capital Management increased its TriSalus Life Sciences (TLSI) stake by 28% in Q2 2026, buying an estimated $1.52M and bringing the position to 1,729,385 shares worth $7.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Vanguard Capital Management first reported a position in TLSI in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Vanguard Capital Management held 1,729,385 shares of TriSalus Life Sciences worth $7.87M as of Q2 2026.
  • Vanguard Capital Management bought 382,349 TriSalus Life Sciences shares in Q2 2026, an estimated $1.52M.
  • TriSalus Life Sciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2949 holding.
  • Vanguard Capital Management first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.